Reactions 1704, p337 - 2 Jun 2018 Recurrent hypertension: case report In a retrospective study that included 41 patients, a patient [age and sex not stated] was described, who developed recurrent hypertension during treatment with rivoceranib [apatinib] for metastatic colorectal cancer [duration of treatment to reaction onset not stated]. The patient, who had metastatic colorectal cancer, received treatment with oral rivoceranib 500mg once daily for 28 days. Prior to the initiation of rivoceranib treatment, the patient had received atleast two lines of chemotherapy [specific drug not stated]. During the rivoceranib therapy, the patient developed recurrent grade 3 hypertension. As the patient’s recurrent hypertension was considered to be related to the use of rivoceranib, the dose of rivoceranib was reduced to 250mg once daily [outcome not stated]. Author comment: "All patients initially received a daily oral dose of 500 mg of apatinib. However, the dose was reduced to 250 mg in one patient due to recurrent grade 3 hypertension." "One dose reduction (to 250 mg) for drug- related grade 3 or 4 toxicity was allowed." Lv W, et al. Efficacy and safety of apatinib in patients with metastatic colorectal cancer refractory to standard therapies. Translational Cancer Research 7: 420-427, No. 2, Apr 2018. Available from: URL: http://doi.org/10.21037/tcr.2018.04.03 - China 803323716 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704
Reactions Weekly – Springer Journals
Published: Jun 2, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera